🇺🇸 BNT162b2 (Omi XBB.1.5)/RIV in United States

BNT162b2 (Omi XBB.1.5)/RIV (bnt162b2-omi-xbb-1-5-riv) regulatory status in United States.

Marketing authorisation

FDA

  • Status: approved

Pricing & reimbursement

BNT162b2 (Omi XBB.1.5)/RIV in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Immunology approved in United States

Frequently asked questions

Is BNT162b2 (Omi XBB.1.5)/RIV approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for BNT162b2 (Omi XBB.1.5)/RIV in United States?

Pfizer is the originator. The local marketing authorisation holder may differ — check the official source linked above.

What does BNT162b2 (Omi XBB.1.5)/RIV cost in United States?

annual_list: USD 80000.00 per year. Final patient cost depends on reimbursement and any patient access scheme.